Navigation Links
BioMS Medical Provides Update On Pipeline Products
Date:5/9/2008

entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical announces conference call and web cast for Annual General Meeting
2. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
3. BioMS Medical to present at EQUITIES Conference
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical to present at BioCentury Conference
6. BioMS Medical Announces 2007 Year End Results
7. BioMS Medical to present at BIO CEO & Investor Conference
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medical announces third quarter 2007 results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Calif., Nov. 21 Accuray,Incorporated (Nasdaq: ARAY ), ... that its president and chief executive officer, Euan S.,Thomson, ... Piper,Jaffray,s Health Care Conference at the Pierre Hotel in ... p.m. EST (9:30 a.m. PST)., A live webcast ...
... TRBN ) today announced that Dr. Peter ... is scheduled to present a,corporate update at the ... held at The New York Palace Hotel. Dr. ... 2:30 p.m. Interested parties may,access the live audio ...
... Nov. 21 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... webcast live during the 19th Annual Piper Jaffray,Health ... 2:30 p.m. Eastern,Time. The presentation will be webcast ... accessed under the Investor Relations tab at ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 2Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 3Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference 219th Annual Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation 2
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Southampton Centre for Biomedical Research, established by the ... the University of Southampton, have been awarded 17m ... research facilities. The funding, which is ... NHS and university partnerships, has secured the future ...
... Ga. A research team from Rollins College in Florida ... the source of the coral-killing pathogen that causes white pox ... in the Caribbean, elkhorn coral was listed for protection under ... to white pox disease. The team,s findings have just been ...
... fecal material -- in particular, dog fecal material -- may ... Detroit,s wintertime air, says a new University of Colorado Boulder ... four Midwestern cities in the experiment, two cities had significant ... feces being the most likely source. "We found ...
Cached Biology News:Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research 2Human pathogen killing corals in the Florida Keys 2Human pathogen killing corals in the Florida Keys 3New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 2New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 3
... The DNA quantitation kit is used to ... the presence of RNA or protein. With this ... which can be detected with a VersaFluor or ... range of 10 ng per ml to 5 ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
... Infinite 200 series of microplate readers combines ... detection in an affordable, easy-to-use platform for ... The unique modular design and adaptability of ... a choice of a monochromator (M200) or ...
...
Biology Products: